Drug Type Bispecific antibody |
Synonyms |
Target |
Action inhibitors |
Mechanism CD276 inhibitors(CD276 antigen inhibitors), CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | China | 22 Mar 2024 |